<DOC>
	<DOCNO>NCT02393716</DOCNO>
	<brief_summary>The purpose study demonstrate Endurant Evo AAA stent graft system safe effective endovascular treatment infrarenal abdominal aortic aortoiliac aneurysm .</brief_summary>
	<brief_title>Endurant Evo US Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm , Abdominal</mesh_term>
	<criteria>1 . Subject ≥18 year old 2 . Subject understand voluntarily sign date Informed Consent approve Sponsor Ethics Committee/Institutional Review Board 3 . Subject able willing comply protocol adhere followup requirement 4 . Subject suitable candidate elective surgical repair AAA evaluate American Society Anesthesiologists ( ASA ) Physical Status Classification System I , II , III 5 . Subject infrarenal abdominal aortic aortoiliac aneurysm characterize one following : Aneurysm &gt; 5 cm diameter ( diameter measure perpendicular line flow ) Aneurysm 4 5 cm diameter increase size ≥0.5 cm within previous 6 month 6 . Subject meet follow anatomical criterion demonstrate contrastenhanced CT MRA imaging : Proximal neck length ≥ 10 mm ≤ 60° infrarenal ≤ 45° suprarenal neck angulation Proximal neck length ≥ 15 mm ≤ 75° infrarenal ≤ 60° suprarenal neck angulation Subject vascular dimension , e.g. , aortic iliac diameter , lengths renal artery iliac bifurcation hypogastric artery , range size available Endurant Evo AAA stent graft system ( measure intima intima ) within size recommendation ( refer Endurant Evo AAA stent graft system Instructions Use ( IFU ) ) Subject proximal aortic neck diameter ≥ 18 mm ≤ 32 mm The distal fixation center iliac artery must diameter ≥ 7 mm ≤ 25 mm bilaterally bifur unilaterally AUI Subject document image evidence least one patent iliac one femoral artery , tolerate vascular conduit allow introduction Endurant Evo AAA stent graft system Subject distal nonaneurysmal iliac ( cylindrical ) fixation length ≥20 mm bilateral bifur unilaterally AUI 1 . Subject life expectancy ≤1 year 2 . Subject participate another investigational drug device study would interfere endpoint followups study 3 . Subject pregnant 4 . Subject aneurysm : Suprarenal/pararenal/juxtarenal Isolated iliofemoral Mycotic Inflammatory Pseudoaneurysm Dissecting Ruptured Leaking rupture 5 . Subject require emergent aneurysm treatment 6 . Subject know , untreated thoracic aneurysm &gt; 4.5 cm diameter time screen 7 . Subject previously treat abdominal aortic aneurysm 8 . Subject history bleed diathesis coagulopathy 9 . Subject plan unrelated major surgical interventional procedure within 1 month implantation Endurant Evo AAA stent graft 10 . Subject myocardial infarction ( MI ) cerebral vascular accident ( CVA ) within 3 month prior implantation Endurant Evo AAA stent graft 11 . Subject conical neck define &gt; 4 mm distal increase low renal artery 10 mm length 12 . Subject know allergy intolerance device material 13 . Subject know hypersensitivity contraindication anticoagulant , antiplatelets , contrast medium , amenable pretreatment 14 . Subject significant aortic thrombus and/or calcification either proximal distal attachment center would compromise fixation seal device discretion investigator 15 . Subject ectatic iliac artery require bilateral exclusion hypogastric blood flow 16 . Subject whose arterial access site anticipate accommodate diameter Endurant Evo AAA stent graft delivery system ( 13F17F ) due vessel size , calcification , tortuosity 17 . Subject morbidly obese document clinical condition severely inhibit radiographic visualization aorta discretion investigator 18 . Subject active infection time index procedure document e.g . pain , fever , drainage , positive culture and/or leukocytosis consider clinically significant per investigator discretion 19 . Subject congenital degenerative collagen disease , e.g. , Marfan 's Syndrome 20 . Subject creatinine level &gt; 2.00 mg/dl ( &gt; 176.8 μmol/L ) 21 . Subject dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>